NZ579566A - Modified fgf-21 polypeptides and their uses - Google Patents

Modified fgf-21 polypeptides and their uses

Info

Publication number
NZ579566A
NZ579566A NZ579566A NZ57956608A NZ579566A NZ 579566 A NZ579566 A NZ 579566A NZ 579566 A NZ579566 A NZ 579566A NZ 57956608 A NZ57956608 A NZ 57956608A NZ 579566 A NZ579566 A NZ 579566A
Authority
NZ
New Zealand
Prior art keywords
amino acid
naturally encoded
encoded amino
polypeptides
acid
Prior art date
Application number
NZ579566A
Inventor
Thomas P Cujec
Roberto Mariani
Putnam Anna-Maria A Hays
William M Keefe
Nick Knudsen
Lillian Ho
Jason Pinkstaff
Vadim Kraynov
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Priority to NZ579566A priority Critical patent/NZ579566A/en
Priority to NZ602702A priority patent/NZ602702A/en
Priority claimed from PCT/US2008/057563 external-priority patent/WO2008121563A2/en
Publication of NZ579566A publication Critical patent/NZ579566A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Provided is a modified human FGF-21 polypeptide comprising a non-naturally encoded amino acid, wherein the non-naturally encoded amino acid has a structure attached to the amino terminal which is any substituent other than a side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, pyrrolysine, or selenocysteine, and wherein the non-naturally encoded amino acid is substituted at a position selected from the group consisting of residues 72, 77, 86, 87, 91, 104, 108, 110, 126, 131, and 146.
NZ579566A 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses NZ579566A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ579566A NZ579566A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses
NZ602702A NZ602702A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2008/057563 WO2008121563A2 (en) 2007-03-30 2008-03-19 Modified fgf-21 polypeptides and their uses
NZ579566A NZ579566A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses

Publications (1)

Publication Number Publication Date
NZ579566A true NZ579566A (en) 2013-01-25

Family

ID=48570579

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ602702A NZ602702A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses
NZ579566A NZ579566A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ602702A NZ602702A (en) 2008-03-19 2008-03-19 Modified fgf-21 polypeptides and their uses

Country Status (1)

Country Link
NZ (2) NZ602702A (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2748038T3 (en) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Compositions, uses and methods for the treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
RS60593B1 (en) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antibodies binding beta klotho domain 2 and methods of use thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX2017004488A (en) 2014-10-23 2017-07-17 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof.
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Also Published As

Publication number Publication date
NZ602702A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
NZ579566A (en) Modified fgf-21 polypeptides and their uses
EP1629840A4 (en) Amino acid composition and fluid replacement
PE20120358A1 (en) FGF21 MUTANTS AND USES OF THEM
HRP20190923T1 (en) Therapeutic agents for reducing parathyroid hormone levels
AR086969A1 (en) CONJUGATE UNDERSTANDING OXONTOMODULIN AND A FRAGMENT OF IMMUNOGLOBULIN, AND ITS USE
PE20120021A1 (en) MUTANTS FGF21
PE20181299A1 (en) NOVELTY OXYNTHOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION TO TREAT OBESITY INCLUDING THEM
WO2007133642A8 (en) Sport drink containing amino acids and carbohydrates
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA95235C2 (en) Glucagon-like-peptide-2 (glp-2) analogues
RU2011154243A (en) CELLULAR OPTIONS WITH IMPROVED EXPRESSION, ACTIVITY AND / OR STABILITY AND THEIR APPLICATION
NZ600732A (en) Oxyntomodulin peptide analogue
ES2273447T3 (en) INSECT RESISTANT TRANSGEN PLANTS AND PROCEDURES TO IMPROVE INSECT ACTIVITY.
PE20121393A1 (en) PEPTIDE ANALOGUE OF OXYNTHOMODULIN
JP2006525288A5 (en)
CO6220904A2 (en) NUCLEIC ACIDS CODING MUTANTS OF ACETOHIDROXIACIDO-SYNTHEASE (AHAS)
CA3010982A1 (en) Alpha chain of the high-affinity ige receptor (fceria)
EP4219547A3 (en) Factor ix polypeptide mutant, its uses and a method for its production
WO2009009727A3 (en) Ghrh analogs and therapeutic uses thereof
EP1908492A4 (en) Metabotropic glutamate receptor activator
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
HRP20191965T1 (en) Stabilized insulin-like growth factor polypeptides
JP2014519526A5 (en)
RU2015146739A (en) COMPLEXES TYPE SUGARIDE CHAIN-POLIPEPTIDE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2015 BY FB RICE

Effective date: 20130612

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2018 BY CPA GLOBAL

Effective date: 20140903

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2021 BY CPA GLOBAL

Effective date: 20140906

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 19 MAR 2028 BY CPA GLOBAL

Effective date: 20140908